Non-small cell lung cancer stage IV+1
Not recruitingStudy on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure
Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure
- Disease:Non-small cell lung cancer stage IVNon-small cell lung cancer stage IIIB
- Substances:Lorlatinib
France- Participants:18–64 years · 65+ years
- Substances:Lorlatinib
- Sponsor:Intergroupe Francophone De Cancerologie Thoracique
